Background: Women with small-cell lung cancer (SCLC) often have longer overall survival (OS) without a corresponding progression-free survival (PFS) advantage. We investigated when this difference emerges.Methods: We conducted a two-cohort secondary analysis. SEER 17 data (2004–2023) assessed associations of sex with all-cause, SCLC-specific, and other-cause mortality. A hospital cohort was analyzed using an illness–death model of documented progression, death without previously documented progression, and death after progression. Multivariable Cox models, Aalen–Johansen state probabilities, restricted mean time in states, and sensitivity analyses were applied.Results: SEER included 107,474 patients and 99,299 deaths. Female sex was associated with lower all-cause mortality (hazard ratio [HR], 0.85; 95% CI, 0.84–0.86), SCLC-specific mortality (HR, 0.86; 95% CI, 0.85–0.87), and other-cause mortality (HR, 0.79; 95% CI, 0.76–0.82). The hospital cohort included 605 patients. Median OS was 17.5 months in women and 10.2 months in men, whereas median PFS was 7.9 and 7.6 months. Adjusted female-to-male HRs were 0.73 (95% CI, 0.55–0.95) for OS and 0.94 (95% CI, 0.75–1.17) for PFS. Female sex was not associated with progression (HR, 1.00; 95% CI, 0.75–1.33) or death without previously documented progression (HR, 0.91; 95% CI, 0.65–1.28), but was associated with lower mortality after progression (HR, 0.43; 95% CI, 0.27–0.68). Through 24 months, women accumulated 1.49 additional months alive after progression without additional progression-free time. The post-progression association persisted in sensitivity analyses and was not modified by recorded immune-checkpoint inhibitor exposure.Conclusions: The female OS advantage in SCLC appears to arise predominantly after documented progression. Prospective studies should examine post-progression treatment, supportive care, host resilience, and relapse biology.